BridgeBio Oncology Therapeutics, Inc Financials
This page shows BridgeBio Oncology Therapeutics, Inc (BBOT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
BridgeBio Oncology Therapeutics, Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, BridgeBio Oncology Therapeutics, Inc generates $0.85 in operating cash flow (-$113.9M OCF vs -$134.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
BridgeBio Oncology Therapeutics, Inc's EBITDA was -$145.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 80.0% from the prior year.
BridgeBio Oncology Therapeutics, Inc reported -$134.0M in net income in fiscal year 2025. This represents a decrease of 80.5% from the prior year.
BridgeBio Oncology Therapeutics, Inc earned $-4.30 per diluted share (EPS) in fiscal year 2025. This represents an increase of 99.9% from the prior year.
Cash & Balance Sheet
BridgeBio Oncology Therapeutics, Inc generated -$114.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 107.9% from the prior year.
BridgeBio Oncology Therapeutics, Inc held $373.7M in cash against $0 in long-term debt as of fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc had 80M shares outstanding in fiscal year 2025. This represents an increase of 281412.5% from the prior year.
Margins & Returns
BridgeBio Oncology Therapeutics, Inc's ROE was -32.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
BridgeBio Oncology Therapeutics, Inc invested $121.2M in research and development in fiscal year 2025. This represents an increase of 65.8% from the prior year.
BridgeBio Oncology Therapeutics, Inc invested $606K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1136.7% from the prior year.
BBOT Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $38.1M+8.6% | $35.1M | N/A | N/A | $19.5M+9.2% | $17.9M | N/A | N/A |
| SG&A Expenses | $5.3M-62.2% | $14.1M+1159.4% | $1.1M-53.7% | $2.4M+3.5% | $2.3M+31.8% | $1.8M+1065.1% | $152K+128.4% | $67K |
| Operating Income | -$43.4M+11.7% | -$49.2M-4283.9% | -$1.1M+53.7% | -$2.4M+88.9% | -$21.9M-11.3% | -$19.7M-12807.7% | -$152K-128.4% | -$67K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | N/A | $0 | N/A | $0 | N/A | N/A |
| Net Income | -$38.8M+13.3% | -$44.8M-57.4% | -$28.4M-28.9% | -$22.1M-12.0% | -$19.7M-13.6% | -$17.3M+20.6% | -$21.8M-41.3% | -$15.4M |
| EPS (Diluted) | $-0.49+52.4% | $-1.03 | N/A | N/A | $-1075.56+31.2% | $-1562.18 | N/A | N/A |
BBOT Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $448.4M-7.5% | $484.8M+145.6% | $197.4M+0.9% | $195.7M+19.1% | $164.3M-14.6% | $192.3M+1.3% | $189.9M+1.3% | $187.5M |
| Current Assets | $432.4M-9.2% | $476.0M+54190.8% | $877K-29.3% | $1.2M-99.2% | $158.7M+7672.2% | $2.0M-1.6% | $2.1M-1.6% | $2.1M |
| Cash & Equivalents | $373.7M-8.6% | $408.7M+61436.0% | $664K-31.0% | $963K-96.9% | $30.9M+51.2% | $20.4M+1024.8% | $1.8M-1.6% | $1.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.3M-2.1% | $38.1M-91.0% | $425.1M+7.4% | $395.7M+15.4% | $342.9M-2.4% | $351.5M+5.5% | $333.3M+5.3% | $316.4M |
| Current Liabilities | $35.0M-1.9% | $35.7M+1258.5% | $2.6M+40.5% | $1.9M-90.4% | $19.6M+15355.0% | $127K+60.1% | $79K+239.2% | $23K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $411.1M-8.0% | $446.7M+296.2% | -$227.7M-13.8% | -$200.0M-12.0% | -$178.6M-12.2% | -$159.2M-11.0% | -$143.4M-11.3% | -$128.9M |
| Retained Earnings | -$356.6M-12.2% | -$317.8M-4269.4% | -$7.3M-18.2% | -$6.2M+97.2% | -$222.5M-6225.6% | -$3.5M-4.3% | -$3.4M-4.7% | -$3.2M |
BBOT Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$42.2M+40.2% | -$70.6M-23528.5% | -$299K+59.3% | -$735K+95.1% | -$15.0M+61.8% | -$39.3M-135110.5% | -$29K+95.3% | -$618K |
| Capital Expenditures | $73K | N/A | N/A | N/A | $10K | N/A | N/A | N/A |
| Free Cash Flow | -$42.3M | N/A | N/A | N/A | -$15.0M | N/A | N/A | N/A |
| Investing Cash Flow | $7.8M | N/A | N/A | N/A | $25.6M-32.6% | $37.9M | $0+100.0% | -$184.0M |
| Financing Cash Flow | -$586K | N/A | N/A | N/A | $52K-99.7% | $19.8M | $0-100.0% | $186.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BBOT Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -9.4%+0.6pp | -10.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.6%+0.6pp | -9.2%+5.2pp | -14.4%-3.1pp | -11.3%+0.7pp | -12.0%-3.0pp | -9.0%+2.5pp | -11.5%-3.3pp | -8.2% |
| Current Ratio | 12.34-1.0 | 13.33+13.0 | 0.33-0.3 | 0.66-7.4 | 8.10-8.0 | 16.12-10.1 | 26.23-64.2 | 90.42 |
| Debt-to-Equity | 0.090.0 | 0.09+2.0 | -1.87+0.1 | -1.98-0.1 | -1.92+0.3 | -2.21+0.1 | -2.32+0.1 | -2.46 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is BridgeBio Oncology Therapeutics, Inc profitable?
No, BridgeBio Oncology Therapeutics, Inc (BBOT) reported a net income of -$134.0M in fiscal year 2025.
What is BridgeBio Oncology Therapeutics, Inc's EBITDA?
BridgeBio Oncology Therapeutics, Inc (BBOT) had EBITDA of -$145.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BridgeBio Oncology Therapeutics, Inc's return on equity (ROE)?
BridgeBio Oncology Therapeutics, Inc (BBOT) has a return on equity of -32.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is BridgeBio Oncology Therapeutics, Inc's free cash flow?
BridgeBio Oncology Therapeutics, Inc (BBOT) generated -$114.5M in free cash flow during fiscal year 2025. This represents a -107.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BridgeBio Oncology Therapeutics, Inc's operating cash flow?
BridgeBio Oncology Therapeutics, Inc (BBOT) generated -$113.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BridgeBio Oncology Therapeutics, Inc's total assets?
BridgeBio Oncology Therapeutics, Inc (BBOT) had $448.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are BridgeBio Oncology Therapeutics, Inc's capital expenditures?
BridgeBio Oncology Therapeutics, Inc (BBOT) invested $606K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BridgeBio Oncology Therapeutics, Inc spend on research and development?
BridgeBio Oncology Therapeutics, Inc (BBOT) invested $121.2M in research and development during fiscal year 2025.
What is BridgeBio Oncology Therapeutics, Inc's current ratio?
BridgeBio Oncology Therapeutics, Inc (BBOT) had a current ratio of 12.34 as of fiscal year 2025, which is generally considered healthy.
What is BridgeBio Oncology Therapeutics, Inc's debt-to-equity ratio?
BridgeBio Oncology Therapeutics, Inc (BBOT) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BridgeBio Oncology Therapeutics, Inc's return on assets (ROA)?
BridgeBio Oncology Therapeutics, Inc (BBOT) had a return on assets of -29.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BridgeBio Oncology Therapeutics, Inc's cash runway?
Based on fiscal year 2025 data, BridgeBio Oncology Therapeutics, Inc (BBOT) had $373.7M in cash against an annual operating cash burn of $113.9M. This gives an estimated cash runway of approximately 39 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is BridgeBio Oncology Therapeutics, Inc's Piotroski F-Score?
BridgeBio Oncology Therapeutics, Inc (BBOT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BridgeBio Oncology Therapeutics, Inc's earnings high quality?
BridgeBio Oncology Therapeutics, Inc (BBOT) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.